ID   AURKA_HUMAN             Reviewed;         403 AA.
AC   O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5;
DT   27-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   27-JAN-2003, sequence version 2.
DT   22-JUL-2015, entry version 178.
DE   RecName: Full=Aurora kinase A;
DE            EC=2.7.11.1;
DE   AltName: Full=Aurora 2;
DE   AltName: Full=Aurora/IPL1-related kinase 1;
DE            Short=ARK-1;
DE            Short=Aurora-related kinase 1;
DE            Short=hARK1;
DE   AltName: Full=Breast tumor-amplified kinase;
DE   AltName: Full=Serine/threonine-protein kinase 15;
DE   AltName: Full=Serine/threonine-protein kinase 6;
DE   AltName: Full=Serine/threonine-protein kinase aurora-A;
GN   Name=AURKA;
GN   Synonyms=AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Blood;
RX   PubMed=9153231; DOI=10.1074/jbc.272.21.13766;
RA   Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K.,
RA   Okano Y.;
RT   "Cell cycle-dependent expression and spindle pole localization of a
RT   novel human protein kinase, Aik, related to Aurora of Drosophila and
RT   yeast Ipl1.";
RL   J. Biol. Chem. 272:13766-13771(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-57.
RX   PubMed=9514916; DOI=10.1006/bbrc.1998.8250;
RA   Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M.,
RA   Gilbert D.J., Jenkins N.A., Copeland N.G., Yagita H., Okumura K.;
RT   "cDNA cloning, expression, subcellular localization, and chromosomal
RT   assignment of mammalian aurora homologues, aurora-related kinase (ARK)
RT   1 and 2.";
RL   Biochem. Biophys. Res. Commun. 244:285-292(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-31.
RC   TISSUE=Mammary gland;
RX   PubMed=9771714; DOI=10.1038/2496;
RA   Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A.,
RA   Brinkley B.R., Sen S.;
RT   "Tumour amplified kinase STK15/BTAK induces centrosome amplification,
RT   aneuploidy and transformation.";
RL   Nat. Genet. 20:189-193(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Wang L., Thibodeau S.N.;
RT   "Mutational analysis of the STK15 gene in human tumors.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, Colon, Kidney, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INDUCTION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9606188; DOI=10.1093/emboj/17.11.3052;
RA   Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B.,
RA   Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S.,
RA   Novotny M., Slamon D.J., Plowman G.D.;
RT   "A homologue of Drosophila aurora kinase is oncogenic and amplified in
RT   human colorectal cancers.";
RL   EMBO J. 17:3052-3065(1998).
RN   [9]
RP   UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205.
RX   PubMed=10851084; DOI=10.1038/sj.onc.1203609;
RA   Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H.,
RA   Furukawa K., Urano T.;
RT   "Degradation of human Aurora2 protein kinase by the anaphase-promoting
RT   complex-ubiquitin-proteasome pathway.";
RL   Oncogene 19:2812-2819(2000).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288,
RP   UBIQUITINATION, AND ENZYME REGULATION.
RX   PubMed=11039908; DOI=10.1038/sj.onc.1203847;
RA   Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.;
RT   "The mitotic serine/threonine kinase Aurora2/AIK is regulated by
RT   phosphorylation and degradation.";
RL   Oncogene 19:4906-4916(2000).
RN   [11]
RP   FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF
RP   PHE-165 AND PHE-346, AND PHOSPHORYLATION.
RX   PubMed=11551964; DOI=10.1074/jbc.M107540200;
RA   Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.;
RT   "Interaction and feedback regulation between STK15/BTAK/Aurora-A
RT   kinase and protein phosphatase 1 through mitotic cell division
RT   cycle.";
RL   J. Biol. Chem. 276:46219-46224(2001).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12576638; DOI=10.1247/csf.27.457;
RA   Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M.,
RA   Dotsu M.;
RT   "Molecular dynamics of Aurora-A kinase in living mitotic cells
RT   simultaneously visualized with histone H3 and nuclear membrane protein
RT   importinalpha.";
RL   Cell Struct. Funct. 27:457-467(2002).
RN   [13]
RP   FUNCTION, INDUCTION, PHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x;
RA   Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D.,
RA   Ichikawa Y., Sasayama T., Kuninaka S., Mimori T., Tamaki N.,
RA   Kimura M., Okano Y., Saya H.;
RT   "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in
RT   mammalian cells.";
RL   Genes Cells 7:1173-1182(2002).
RN   [14]
RP   INDUCTION.
RX   PubMed=11790771; DOI=10.1074/jbc.M108252200;
RA   Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S.,
RA   Ishigatsubo Y.;
RT   "Cell-cycle-dependent regulation of human aurora A transcription is
RT   mediated by periodic repression of E4TF1.";
RL   J. Biol. Chem. 277:10719-10726(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288.
RX   PubMed=13678582; DOI=10.1016/S0092-8674(03)00642-1;
RA   Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M.,
RA   Hatakeyama K., Saya H.;
RT   "Aurora-A and an interacting activator, the LIM protein Ajuba, are
RT   required for mitotic commitment in human cells.";
RL   Cell 114:585-598(2003).
RN   [16]
RP   FUNCTION.
RX   PubMed=14523000; DOI=10.1074/jbc.M306275200;
RA   Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E.,
RA   Saya H.;
RT   "Aurora-A kinase maintains the fidelity of early and late mitotic
RT   events in HeLa cells.";
RL   J. Biol. Chem. 278:51786-51795(2003).
RN   [17]
RP   INTERACTION WITH TACC1.
RX   PubMed=14603251; DOI=10.1038/sj.onc.1206972;
RA   Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D.,
RA   Larroque C., Prigent C., Seraphin B., Jacquemier J., Birnbaum D.;
RT   "TACC1-chTOG-Aurora A protein complex in breast cancer.";
RL   Oncogene 22:8102-8116(2003).
RN   [18]
RP   FUNCTION.
RX   PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x;
RA   Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S.,
RA   Tamai K., Nojima H.;
RT   "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A
RT   kinase.";
RL   Genes Cells 9:383-397(2004).
RN   [19]
RP   FUNCTION, INTERACTION WITH BRCA1, PHOSPHORYLATION AT THR-288, AND
RP   MUTAGENESIS OF LYS-162.
RX   PubMed=14990569; DOI=10.1074/jbc.M311780200;
RA   Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A.,
RA   Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.;
RT   "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M
RT   transition.";
RL   J. Biol. Chem. 279:19643-19648(2004).
RN   [20]
RP   FUNCTION.
RX   PubMed=15128871; DOI=10.1242/jcs.01108;
RA   Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V.,
RA   Dozier C., Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E.,
RA   Monsarrat B., Prigent C., Ducommun B.;
RT   "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes
RT   to the G2-M transition.";
RL   J. Cell Sci. 117:2523-2531(2004).
RN   [21]
RP   FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated
RT   destabilization and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [22]
RP   INTERACTION WITH CPEB1.
RX   PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x;
RA   Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N.,
RA   Kohmura E., Saya H., Hirota T.;
RT   "Over-expression of Aurora-A targets cytoplasmic polyadenylation
RT   element binding protein and promotes mRNA polyadenylation of Cdk1 and
RT   cyclin B1.";
RL   Genes Cells 10:627-638(2005).
RN   [23]
RP   PHOSPHORYLATION AT THR-288 AND SER-342.
RX   PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035;
RA   Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.;
RT   "The GIT-associated kinase PAK targets to the centrosome and regulates
RT   Aurora-A.";
RL   Mol. Cell 20:237-249(2005).
RN   [24]
RP   INDUCTION, AND FUNCTION.
RX   PubMed=15987997; DOI=10.1128/MCB.25.14.5789-5800.2005;
RA   Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.;
RT   "Phosphorylation and stabilization of HURP by Aurora-A: implication of
RT   HURP as a transforming target of Aurora-A.";
RL   Mol. Cell. Biol. 25:5789-5800(2005).
RN   [25]
RP   INTERACTION WITH BORA.
RX   PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002;
RA   Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A.,
RA   Knoblich J.A.;
RT   "Mitotic activation of the kinase Aurora-A requires its binding
RT   partner Bora.";
RL   Dev. Cell 11:147-157(2006).
RN   [26]
RP   FUNCTION.
RX   PubMed=18056443; DOI=10.1158/0008-5472.CAN-07-2578;
RA   Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.;
RT   "Aurora-A kinase regulates breast cancer associated gene 1 inhibition
RT   of centrosome-dependent microtubule nucleation.";
RL   Cancer Res. 67:11186-11194(2007).
RN   [27]
RP   FUNCTION.
RX   PubMed=17604723; DOI=10.1016/j.cell.2007.04.035;
RA   Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P.,
RA   Golemis E.A.;
RT   "HEF1-dependent Aurora A activation induces disassembly of the primary
RT   cilium.";
RL   Cell 129:1351-1363(2007).
RN   [28]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014;
RA   Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M.,
RA   Bokoch G.M.;
RT   "GEF-H1 modulates localized RhoA activation during cytokinesis under
RT   the control of mitotic kinases.";
RL   Dev. Cell 12:699-712(2007).
RN   [29]
RP   SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT
RP   SER-51.
RX   PubMed=17229885; DOI=10.1091/mbc.E06-12-1152;
RA   Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.;
RT   "Functional interaction of Aurora-A and PP2A during mitosis.";
RL   Mol. Biol. Cell 18:1233-1241(2007).
RN   [30]
RP   INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION.
RX   PubMed=17726514; DOI=10.1371/journal.pone.0000784;
RA   North B.J., Verdin E.;
RT   "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2
RT   during mitosis.";
RL   PLoS ONE 2:E784-E784(2007).
RN   [31]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=17360485; DOI=10.1073/pnas.0608798104;
RA   Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O.,
RA   Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T.,
RA   Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S.,
RA   Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.;
RT   "Antitumor activity of MLN8054, an orally active small-molecule
RT   inhibitor of Aurora A kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [33]
RP   FUNCTION.
RX   PubMed=18615013; DOI=10.1038/nature07185;
RA   Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R.,
RA   Freire R., Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.;
RT   "Polo-like kinase-1 is activated by aurora A to promote checkpoint
RT   recovery.";
RL   Nature 455:119-123(2008).
RN   [34]
RP   FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3.
RX   PubMed=19812038; DOI=10.1074/jbc.M109.055897;
RA   Khazaei M.R., Puschel A.W.;
RT   "Phosphorylation of the par polarity complex protein Par3 at serine
RT   962 is mediated by aurora A and regulates its function in neuronal
RT   polarity.";
RL   J. Biol. Chem. 284:33571-33579(2009).
RN   [35]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A.
RX   PubMed=19351716; DOI=10.1242/jcs.044321;
RA   Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.;
RT   "Plk1 and Aurora A regulate the depolymerase activity and the cellular
RT   localization of Kif2a.";
RL   J. Cell Sci. 122:1334-1341(2009).
RN   [36]
RP   FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND
RP   THR-288, AND MUTAGENESIS OF THR-287.
RX   PubMed=19668197; DOI=10.1038/ncb1919;
RA   Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S.,
RA   Saya H., Wynshaw-Boris A., Hirotsune S.;
RT   "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite
RT   elongation by modulation of microtubule dynamics.";
RL   Nat. Cell Biol. 11:1057-1068(2009).
RN   [37]
RP   INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, SUBCELLULAR LOCATION,
RP   AND FUNCTION.
RX   PubMed=19357306; DOI=10.1073/pnas.0900833106;
RA   Fu J., Bian M., Liu J., Jiang Q., Zhang C.;
RT   "A single amino acid change converts Aurora-A into Aurora-B-like
RT   kinase in terms of partner specificity and cellular function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009).
RN   [38]
RP   FUNCTION, INTERACTION WITH PIFO, AND ACTIVATION BY PIFO.
RX   PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005;
RA   Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B.,
RA   Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.;
RT   "Pitchfork regulates primary cilia disassembly and left-right
RT   asymmetry.";
RL   Dev. Cell 19:66-77(2010).
RN   [39]
RP   INTERACTION WITH AUNIP.
RX   PubMed=20596670;
RA   Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y.,
RA   Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.;
RT   "Functional characterization of AIBp, a novel Aurora-A binding protein
RT   in centrosome structure and spindle formation.";
RL   Int. J. Oncol. 37:429-436(2010).
RN   [40]
RP   INTERACTION WITH GADD45A.
RX   PubMed=20460379; DOI=10.1074/jbc.M109.069344;
RA   Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J.,
RA   Montoya G., Campos-Olivas R., Blanco F.J.;
RT   "Solution structure of human growth arrest and DNA damage 45alpha
RT   (Gadd45alpha) and its interactions with proliferating cell nuclear
RT   antigen (PCNA) and Aurora A kinase.";
RL   J. Biol. Chem. 285:22196-22201(2010).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [42]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH JTB.
RX   PubMed=21225229; DOI=10.3892/ijo.2011.900;
RA   Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.;
RT   "PAR, a protein involved in the cell cycle, is functionally related to
RT   chromosomal passenger proteins.";
RL   Int. J. Oncol. 38:777-785(2011).
RN   [43]
RP   REVIEW ON FUNCTION.
RX   PubMed=14625535; DOI=10.1038/nrm1245;
RA   Carmena M., Earnshaw W.C.;
RT   "The cellular geography of aurora kinases.";
RL   Nat. Rev. Mol. Cell Biol. 4:842-854(2003).
RN   [44]
RP   REVIEW ON FUNCTION.
RX   PubMed=19774610; DOI=10.1002/em.20533;
RA   Lukasiewicz K.B., Lingle W.L.;
RT   "Aurora A, centrosome structure, and the centrosome cycle.";
RL   Environ. Mol. Mutagen. 50:602-619(2009).
RN   [45]
RP   INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION.
RX   PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004;
RA   Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X.,
RA   Li C., Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H.,
RA   Cha Y.I., Gius D., Deng C.X.;
RT   "SIRT2 maintains genome integrity and suppresses tumorigenesis through
RT   regulating APC/C activity.";
RL   Cancer Cell 20:487-499(2011).
RN   [46]
RP   INTERACTION WITH FRY.
RX   PubMed=22753416; DOI=10.1074/jbc.M112.378968;
RA   Ikeda M., Chiba S., Ohashi K., Mizuno K.;
RT   "Furry protein promotes Aurora A-mediated polo-like kinase 1
RT   activation.";
RL   J. Biol. Chem. 287:27670-27681(2012).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH
RP   ADENOSINE, AND CATALYTIC ACTIVITY.
RX   PubMed=12237287; DOI=10.1074/jbc.C200426200;
RA   Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L.,
RA   Weber P., Lippke J.A., Austen D.A.;
RT   "Crystal structure of aurora-2, an oncogenic serine/threonine
RT   kinase.";
RL   J. Biol. Chem. 277:42419-42422(2002).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP.
RX   PubMed=12467573; DOI=10.1016/S0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein
RT   kinases from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2,
RP   MUTAGENESIS OF ASP-274, ACTIVE SITE, AND PHOSPHORYLATION AT THR-287
RP   AND THR-288.
RX   PubMed=14580337; DOI=10.1016/S1097-2765(03)00392-7;
RA   Bayliss R., Sardon T., Vernos I., Conti E.;
RT   "Structural basis of Aurora-A activation by TPX2 at the mitotic
RT   spindle.";
RL   Mol. Cell 12:851-862(2003).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH
RP   ADPNP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053;
RA   Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S.,
RA   Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A.,
RA   Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.;
RT   "SAR and inhibitor complex structure determination of a novel class of
RT   potent and specific Aurora kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 16:1320-1323(2006).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH
RP   SYNTHETIC INHIBITORS, AND FUNCTION.
RX   PubMed=17125279; DOI=10.1021/jm060897w;
RA   Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D.,
RA   Bindi S., Cameron A., Candiani I., Cappella P., Carpinelli P.,
RA   Croci W., Forte B., Giorgini M.L., Klapwijk J., Marsiglio A.,
RA   Pesenti E., Rocchetti M., Roletto F., Severino D., Soncini C.,
RA   Storici P., Tonani R., Zugnoni P., Vianello P.;
RT   "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent
RT   aurora kinase inhibitor with a favorable antitumor kinase inhibition
RT   profile.";
RL   J. Med. Chem. 49:7247-7251(2006).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH
RP   VX-680 AND TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND SUBUNIT.
RX   PubMed=18662907; DOI=10.1110/ps.036590.108;
RA   Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A.,
RA   Kirkpatrick R.B., Lai Z.;
RT   "Modulation of kinase-inhibitor interactions by auxiliary protein
RT   binding: crystallography studies on Aurora A interactions with VX-680
RT   and with TPX2.";
RL   Protein Sci. 17:1791-1797(2008).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP,
RP   CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH
RP   TPX2.
RX   PubMed=19801554; DOI=10.1074/jbc.M109.032722;
RA   Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R.,
RA   Bayliss R., Linardopoulos S.;
RT   "A cancer-associated aurora A mutant is mislocalized and misregulated
RT   due to loss of interaction with TPX2.";
RL   J. Biol. Chem. 284:33177-33184(2009).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19140666; DOI=10.1021/jm801270e;
RA   Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H.,
RA   Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S.,
RA   Wu S.Y., Hsieh H.P.;
RT   "Structure-based drug design of novel Aurora kinase A inhibitors:
RT   structural basis for potency and specificity.";
RL   J. Med. Chem. 52:1050-1062(2009).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19402633; DOI=10.1021/jm9000314;
RA   Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J.,
RA   Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E.,
RA   Liang J., Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M.,
RA   Walker L., Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.;
RT   "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with
RT   unusually high selectivity against Aurora B.";
RL   J. Med. Chem. 52:3300-3307(2009).
RN   [56]
RP   VARIANTS ILE-31 AND ILE-57.
RX   PubMed=15867347; DOI=10.1158/0008-5472.CAN-04-2149;
RA   Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K.,
RA   Nagase H.;
RT   "Two functional coding single nucleotide polymorphisms in STK15
RT   (Aurora-A) coordinately increase esophageal cancer risk.";
RL   Cancer Res. 65:3548-3554(2005).
RN   [57]
RP   VARIANTS ILE-31 AND ILE-57.
RX   PubMed=16011022;
RA   Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y.,
RA   Xu H.M., Zhang X.;
RT   "Linkage disequilibrium and haplotype analysis of two single
RT   nucleotide polymorphisms in STK15 in Chinese.";
RL   Yi Chuan Xue Bao 32:331-336(2005).
RN   [58]
RP   VARIANT ILE-31.
RX   PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002;
RA   Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A.,
RA   Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K.,
RA   Bartram C.R., Burwinkel B.;
RT   "Aurora kinases A and B and familial breast cancer risk.";
RL   Cancer Lett. 247:266-272(2007).
RN   [59]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; ILE-57; ARG-155;
RP   MET-174 AND VAL-373.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Mitotic serine/threonine kinases that contributes to the
CC       regulation of cell cycle progression. Associates with the
CC       centrosome and the spindle microtubules during mitosis and plays a
CC       critical role in various mitotic events including the
CC       establishment of mitotic spindle, centrosome duplication,
CC       centrosome separation as well as maturation, chromosomal
CC       alignment, spindle assembly checkpoint, and cytokinesis. Required
CC       for initial activation of CDK1 at centrosomes. Phosphorylates
CC       numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B,
CC       DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1,
CC       TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase
CC       activity. Required for normal axon formation. Plays a role in
CC       microtubule remodeling during neurite extension. Important for
CC       microtubule formation and/or stabilization. Also acts as a key
CC       regulatory component of the p53/TP53 pathway, and particularly the
CC       checkpoint-response pathways critical for oncogenic transformation
CC       of cells, by phosphorylating and stabilizing p53/TP53.
CC       Phosphorylates its own inhibitors, the protein phosphatase type 1
CC       (PP1) isoforms, to inhibit their activity. Necessary for proper
CC       cilia disassembly prior to mitosis. {ECO:0000269|PubMed:11039908,
CC       ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12390251,
CC       ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14523000,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:14990569,
CC       ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269,
CC       ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279,
CC       ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723,
CC       ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013,
CC       ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306,
CC       ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:19812038,
CC       ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:9606188}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122,
CC       ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633}.
CC   -!- ENZYME REGULATION: Activation of CDK1, appears to be an upstream
CC       event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and
CC       TPX2 act also as activators. Inactivated by the G2 checkpoint.
CC       Inhibited by GADD45A and p53/TP53, and through dephosphorylation
CC       by protein phosphatase type 1 (PP1). MLN8054 is also a potent and
CC       selective inhibitor. Activated during the early phase of cilia
CC       disassembly in the presence of PIFO. {ECO:0000269|PubMed:11039908,
CC       ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485}.
CC   -!- SUBUNIT: Interacts with FBXL7 (By similarity). Interacts with
CC       CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the protein
CC       phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC.
CC       Interacts also with its substrates ARHGEF2, BORA, BRCA1, KIF2A,
CC       PARD3, and p53/TP53. Interaction with BORA promotes
CC       phosphorylation of PLK1. Interacts with PIFO. Interacts with
CC       GADD45A, competing with its oligomerization. Interacts (via C-
CC       terminus) with AUNIP (via C-terminus). Identified in a complex
CC       with AUNIP and NIN. Interacts with FRY; this interaction
CC       facilitates AURKA-mediated PLK1 phosphorylation. Interacts with
CC       SIRT2. {ECO:0000250, ECO:0000269|PubMed:11551964,
CC       ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:12467573,
CC       ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:14603251,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:14990569,
CC       ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155,
CC       ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622,
CC       ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:18662907,
CC       ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19351716,
CC       ECO:0000269|PubMed:19357306, ECO:0000269|PubMed:19402633,
CC       ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:19801554,
CC       ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20460379,
CC       ECO:0000269|PubMed:20596670, ECO:0000269|PubMed:20643351,
CC       ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574,
CC       ECO:0000269|PubMed:22753416}.
CC   -!- INTERACTION:
CC       Q9NWT8:AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665;
CC       P00533:EGFR; NbExp=4; IntAct=EBI-448680, EBI-297353;
CC       P61978:HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185;
CC       Q13123:IK; NbExp=3; IntAct=EBI-448680, EBI-713456;
CC       P04198:MYCN; NbExp=9; IntAct=EBI-448680, EBI-878369;
CC       P06748:NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579;
CC       Q8VDQ8:Sirt2 (xeno); NbExp=5; IntAct=EBI-448680, EBI-911012;
CC       O15350:TP73; NbExp=11; IntAct=EBI-448680, EBI-389606;
CC       Q9ULW0:TPX2; NbExp=2; IntAct=EBI-448680, EBI-1037322;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome. Cytoplasm, cytoskeleton, spindle
CC       pole. Note=Detected at the neurite hillock in developing neurons
CC       (By similarity). Localizes at the centrosome in mitotic cells from
CC       early prophase until telophase, but also localizes to the spindle
CC       pole MTs from prophase to anaphase. Colocalized with SIRT2 at
CC       centrosome. Moves to the midbody during both telophase and
CC       cytokinesis. Associates with both the pericentriolar material
CC       (PCM) and centrioles. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in
CC       skeletal muscle, thymus and spleen. Also highly expressed in
CC       colon, ovarian, prostate, neuroblastoma, breast and cervical
CC       cancer cell lines.
CC   -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S,
CC       accumulates during G2/M, and decreases rapidly after.
CC       {ECO:0000269|PubMed:11790771, ECO:0000269|PubMed:12390251,
CC       ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:9153231,
CC       ECO:0000269|PubMed:9606188}.
CC   -!- PTM: Activated by phosphorylation at Thr-288; this brings about a
CC       change in the conformation of the activation segment.
CC       Phosphorylation at Thr-288 varies during the cell cycle and is
CC       highest during M phase. Autophosphorylated at Thr-288 upon TPX2
CC       binding. Thr-288 can be phosphorylated by several kinases,
CC       including PAK and PKA. Protein phosphatase type 1 (PP1) binds
CC       AURKA and inhibits its activity by dephosphorylating Thr-288
CC       during mitosis. Phosphorylation at Ser-342 decreases the kinase
CC       activity. PPP2CA controls degradation by dephosphorylating Ser-51
CC       at the end of mitosis. {ECO:0000269|PubMed:11039908,
CC       ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12390251,
CC       ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337,
CC       ECO:0000269|PubMed:14990569, ECO:0000269|PubMed:16246726,
CC       ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907,
CC       ECO:0000269|PubMed:19668197}.
CC   -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex
CC       SCF(FBXL7) during mitosis, leading to its degradation by the
CC       proteasome. Ubiquitinated by CHFR, leading to its degradation by
CC       the proteasome (By similarity). Ubiquitinated by the anaphase-
CC       promoting complex (APC), leading to its degradation by the
CC       proteasome. {ECO:0000250, ECO:0000269|PubMed:10851084,
CC       ECO:0000269|PubMed:11039908}.
CC   -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles
CC       are uncoupled, and this amplification is associated with cancer
CC       and with an increase in the levels of chromosomal instability.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. Aurora subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2
CC       different proteins (PubMed:9771714). It is clear that they are the
CC       same protein. {ECO:0000305|PubMed:9771714}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA23592.1; Type=Frameshift; Positions=105, 125, 129, 235, 241; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AURKAID730ch20q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA.
DR   EMBL; AF008551; AAC12708.1; -; mRNA.
DR   EMBL; AF011467; AAC23448.1; -; Genomic_DNA.
DR   EMBL; AF011468; AAC63902.1; -; mRNA.
DR   EMBL; AF195947; AAF29508.1; -; Genomic_DNA.
DR   EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AL121914; CAC12717.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75550.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75551.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75552.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75553.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75554.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75555.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75556.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75557.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75558.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75559.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75561.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75562.1; -; Genomic_DNA.
DR   EMBL; BC001280; AAH01280.1; -; mRNA.
DR   EMBL; BC002499; AAH02499.1; -; mRNA.
DR   EMBL; BC006423; AAH06423.1; -; mRNA.
DR   EMBL; BC027464; AAH27464.1; -; mRNA.
DR   CCDS; CCDS13451.1; -.
DR   PIR; JC5974; JC5974.
DR   RefSeq; NP_003591.2; NM_003600.2.
DR   RefSeq; NP_940835.1; NM_198433.1.
DR   RefSeq; NP_940836.1; NM_198434.1.
DR   RefSeq; NP_940837.1; NM_198435.1.
DR   RefSeq; NP_940838.1; NM_198436.1.
DR   RefSeq; NP_940839.1; NM_198437.1.
DR   RefSeq; XP_005260591.1; XM_005260534.1.
DR   RefSeq; XP_006723935.1; XM_006723872.1.
DR   UniGene; Hs.250822; -.
DR   PDB; 1MQ4; X-ray; 1.90 A; A=125-391.
DR   PDB; 1MUO; X-ray; 2.90 A; A=107-403.
DR   PDB; 1OL5; X-ray; 2.50 A; A=122-403.
DR   PDB; 1OL6; X-ray; 3.00 A; A=122-403.
DR   PDB; 1OL7; X-ray; 2.75 A; A=122-403.
DR   PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403.
DR   PDB; 2C6D; X-ray; 2.20 A; A=124-398.
DR   PDB; 2C6E; X-ray; 2.10 A; A/B=123-401.
DR   PDB; 2DWB; X-ray; 2.50 A; A=122-403.
DR   PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403.
DR   PDB; 2J50; X-ray; 3.00 A; A/B=126-403.
DR   PDB; 2NP8; X-ray; 2.25 A; A=125-391.
DR   PDB; 2W1C; X-ray; 3.24 A; A=122-389.
DR   PDB; 2W1D; X-ray; 2.97 A; A=122-389.
DR   PDB; 2W1E; X-ray; 2.93 A; A=122-389.
DR   PDB; 2W1F; X-ray; 2.85 A; A=122-389.
DR   PDB; 2W1G; X-ray; 2.71 A; A=122-389.
DR   PDB; 2WQE; X-ray; 2.50 A; A=127-388.
DR   PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403.
DR   PDB; 2WTW; X-ray; 3.30 A; A=122-403.
DR   PDB; 2X6D; X-ray; 2.80 A; A=122-403.
DR   PDB; 2X6E; X-ray; 3.35 A; A=122-403.
DR   PDB; 2X81; X-ray; 2.91 A; A=126-391.
DR   PDB; 2XNE; X-ray; 2.80 A; A=122-392.
DR   PDB; 2XNG; X-ray; 2.60 A; A=122-403.
DR   PDB; 2XRU; X-ray; 2.90 A; A=126-403.
DR   PDB; 3COH; X-ray; 2.70 A; A/B=124-391.
DR   PDB; 3E5A; X-ray; 2.30 A; A=125-391.
DR   PDB; 3EFW; X-ray; 2.29 A; A/B=125-391.
DR   PDB; 3FDN; X-ray; 1.90 A; A=123-401.
DR   PDB; 3H0Y; X-ray; 2.50 A; A=124-391.
DR   PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391.
DR   PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391.
DR   PDB; 3HA6; X-ray; 2.36 A; A=125-391.
DR   PDB; 3K5U; X-ray; 2.35 A; A=123-401.
DR   PDB; 3LAU; X-ray; 2.10 A; A=125-399.
DR   PDB; 3M11; X-ray; 2.75 A; A=123-401.
DR   PDB; 3MYG; X-ray; 2.40 A; A=125-391.
DR   PDB; 3NRM; X-ray; 3.05 A; A=126-403.
DR   PDB; 3O50; X-ray; 2.00 A; A/B=125-391.
DR   PDB; 3O51; X-ray; 3.20 A; A=125-391.
DR   PDB; 3P9J; X-ray; 2.80 A; A=125-391.
DR   PDB; 3QBN; X-ray; 3.50 A; A=124-403.
DR   PDB; 3R21; X-ray; 2.90 A; A=126-391.
DR   PDB; 3R22; X-ray; 2.90 A; A=126-391.
DR   PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401.
DR   PDB; 3UO4; X-ray; 2.45 A; A=123-401.
DR   PDB; 3UO5; X-ray; 2.70 A; A=123-401.
DR   PDB; 3UO6; X-ray; 2.80 A; A/B=123-401.
DR   PDB; 3UOD; X-ray; 2.50 A; A=123-401.
DR   PDB; 3UOH; X-ray; 2.80 A; A/B=123-401.
DR   PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401.
DR   PDB; 3UOK; X-ray; 2.95 A; A/B=123-401.
DR   PDB; 3UOL; X-ray; 2.40 A; A/B=123-401.
DR   PDB; 3UP2; X-ray; 2.30 A; A=123-401.
DR   PDB; 3UP7; X-ray; 3.05 A; A=123-401.
DR   PDB; 3VAP; X-ray; 2.66 A; A=125-391.
DR   PDB; 3W10; X-ray; 2.70 A; A=126-403.
DR   PDB; 3W16; X-ray; 2.80 A; A=126-403.
DR   PDB; 3W18; X-ray; 2.50 A; A/B=126-403.
DR   PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388.
DR   PDB; 4B0G; X-ray; 2.50 A; A=122-403.
DR   PDB; 4BN1; X-ray; 2.50 A; A=122-403.
DR   PDB; 4BYI; X-ray; 2.60 A; A=122-403.
DR   PDB; 4BYJ; X-ray; 2.75 A; A=122-403.
DR   PDB; 4C3P; X-ray; 2.69 A; A/D=122-403.
DR   PDB; 4C3R; X-ray; 2.79 A; A=122-403.
DR   PDB; 4CEG; X-ray; 2.10 A; A=122-403.
DR   PDB; 4DEA; X-ray; 2.45 A; A=123-401.
DR   PDB; 4DEB; X-ray; 3.05 A; A=123-401.
DR   PDB; 4DED; X-ray; 3.05 A; A=123-401.
DR   PDB; 4DEE; X-ray; 2.30 A; A=123-401.
DR   PDB; 4DHF; X-ray; 2.80 A; A/B=126-391.
DR   PDB; 4J8M; X-ray; 1.85 A; A=123-401.
DR   PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401.
DR   PDB; 4JAI; X-ray; 3.20 A; A=122-396.
DR   PDB; 4JAJ; X-ray; 2.70 A; A=122-396.
DR   PDB; 4JBO; X-ray; 2.49 A; A=123-401.
DR   PDB; 4JBP; X-ray; 2.45 A; A=123-401.
DR   PDB; 4JBQ; X-ray; 2.30 A; A=123-401.
DR   PDB; 4O0S; X-ray; 2.50 A; A=122-403.
DR   PDB; 4O0U; X-ray; 2.60 A; A=122-403.
DR   PDB; 4O0W; X-ray; 2.60 A; A=122-403.
DR   PDB; 4PRJ; X-ray; 2.80 A; A=124-391.
DR   PDB; 4UYN; X-ray; 1.90 A; A=125-399.
DR   PDB; 4UZD; X-ray; 3.20 A; A/B=125-399.
DR   PDB; 4UZH; X-ray; 2.00 A; A=125-399.
DR   PDBsum; 1MQ4; -.
DR   PDBsum; 1MUO; -.
DR   PDBsum; 1OL5; -.
DR   PDBsum; 1OL6; -.
DR   PDBsum; 1OL7; -.
DR   PDBsum; 2BMC; -.
DR   PDBsum; 2C6D; -.
DR   PDBsum; 2C6E; -.
DR   PDBsum; 2DWB; -.
DR   PDBsum; 2J4Z; -.
DR   PDBsum; 2J50; -.
DR   PDBsum; 2NP8; -.
DR   PDBsum; 2W1C; -.
DR   PDBsum; 2W1D; -.
DR   PDBsum; 2W1E; -.
DR   PDBsum; 2W1F; -.
DR   PDBsum; 2W1G; -.
DR   PDBsum; 2WQE; -.
DR   PDBsum; 2WTV; -.
DR   PDBsum; 2WTW; -.
DR   PDBsum; 2X6D; -.
DR   PDBsum; 2X6E; -.
DR   PDBsum; 2X81; -.
DR   PDBsum; 2XNE; -.
DR   PDBsum; 2XNG; -.
DR   PDBsum; 2XRU; -.
DR   PDBsum; 3COH; -.
DR   PDBsum; 3E5A; -.
DR   PDBsum; 3EFW; -.
DR   PDBsum; 3FDN; -.
DR   PDBsum; 3H0Y; -.
DR   PDBsum; 3H0Z; -.
DR   PDBsum; 3H10; -.
DR   PDBsum; 3HA6; -.
DR   PDBsum; 3K5U; -.
DR   PDBsum; 3LAU; -.
DR   PDBsum; 3M11; -.
DR   PDBsum; 3MYG; -.
DR   PDBsum; 3NRM; -.
DR   PDBsum; 3O50; -.
DR   PDBsum; 3O51; -.
DR   PDBsum; 3P9J; -.
DR   PDBsum; 3QBN; -.
DR   PDBsum; 3R21; -.
DR   PDBsum; 3R22; -.
DR   PDBsum; 3UNZ; -.
DR   PDBsum; 3UO4; -.
DR   PDBsum; 3UO5; -.
DR   PDBsum; 3UO6; -.
DR   PDBsum; 3UOD; -.
DR   PDBsum; 3UOH; -.
DR   PDBsum; 3UOJ; -.
DR   PDBsum; 3UOK; -.
DR   PDBsum; 3UOL; -.
DR   PDBsum; 3UP2; -.
DR   PDBsum; 3UP7; -.
DR   PDBsum; 3VAP; -.
DR   PDBsum; 3W10; -.
DR   PDBsum; 3W16; -.
DR   PDBsum; 3W18; -.
DR   PDBsum; 3W2C; -.
DR   PDBsum; 4B0G; -.
DR   PDBsum; 4BN1; -.
DR   PDBsum; 4BYI; -.
DR   PDBsum; 4BYJ; -.
DR   PDBsum; 4C3P; -.
DR   PDBsum; 4C3R; -.
DR   PDBsum; 4CEG; -.
DR   PDBsum; 4DEA; -.
DR   PDBsum; 4DEB; -.
DR   PDBsum; 4DED; -.
DR   PDBsum; 4DEE; -.
DR   PDBsum; 4DHF; -.
DR   PDBsum; 4J8M; -.
DR   PDBsum; 4J8N; -.
DR   PDBsum; 4JAI; -.
DR   PDBsum; 4JAJ; -.
DR   PDBsum; 4JBO; -.
DR   PDBsum; 4JBP; -.
DR   PDBsum; 4JBQ; -.
DR   PDBsum; 4O0S; -.
DR   PDBsum; 4O0U; -.
DR   PDBsum; 4O0W; -.
DR   PDBsum; 4PRJ; -.
DR   PDBsum; 4UYN; -.
DR   PDBsum; 4UZD; -.
DR   PDBsum; 4UZH; -.
DR   ProteinModelPortal; O14965; -.
DR   SMR; O14965; 76-394.
DR   BioGrid; 112666; 217.
DR   DIP; DIP-33068N; -.
DR   IntAct; O14965; 73.
DR   MINT; MINT-254096; -.
DR   STRING; 9606.ENSP00000216911; -.
DR   BindingDB; O14965; -.
DR   ChEMBL; CHEMBL4722; -.
DR   GuidetoPHARMACOLOGY; 1936; -.
DR   PhosphoSite; O14965; -.
DR   BioMuta; AURKA; -.
DR   MaxQB; O14965; -.
DR   PaxDb; O14965; -.
DR   PRIDE; O14965; -.
DR   DNASU; 6790; -.
DR   Ensembl; ENST00000312783; ENSP00000321591; ENSG00000087586.
DR   Ensembl; ENST00000347343; ENSP00000216911; ENSG00000087586.
DR   Ensembl; ENST00000371356; ENSP00000360407; ENSG00000087586.
DR   Ensembl; ENST00000395911; ENSP00000379247; ENSG00000087586.
DR   Ensembl; ENST00000395913; ENSP00000379249; ENSG00000087586.
DR   Ensembl; ENST00000395914; ENSP00000379250; ENSG00000087586.
DR   Ensembl; ENST00000395915; ENSP00000379251; ENSG00000087586.
DR   GeneID; 6790; -.
DR   KEGG; hsa:6790; -.
DR   UCSC; uc002xxd.1; human.
DR   CTD; 6790; -.
DR   GeneCards; GC20M054944; -.
DR   H-InvDB; HIX0015930; -.
DR   HGNC; HGNC:11393; AURKA.
DR   HPA; CAB001454; -.
DR   HPA; HPA002636; -.
DR   MIM; 603072; gene.
DR   neXtProt; NX_O14965; -.
DR   PharmGKB; PA36201; -.
DR   eggNOG; COG0515; -.
DR   HOVERGEN; HBG108519; -.
DR   InParanoid; O14965; -.
DR   KO; K11481; -.
DR   OrthoDB; EOG74FF1F; -.
DR   PhylomeDB; O14965; -.
DR   TreeFam; TF105331; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_160315; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; REACT_6761; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1.
DR   SignaLink; O14965; -.
DR   EvolutionaryTrace; O14965; -.
DR   GeneWiki; Aurora_A_kinase; -.
DR   GenomeRNAi; 6790; -.
DR   NextBio; 26512; -.
DR   PRO; PR:O14965; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; O14965; -.
DR   CleanEx; HS_AURKA; -.
DR   ExpressionAtlas; O14965; baseline and differential.
DR   Genevisible; O14965; HS.
DR   GO; GO:0043203; C:axon hillock; IEA:Ensembl.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central.
DR   GO; GO:0000780; C:condensed nuclear chromosome, centromeric region; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0042585; C:germinal vesicle; IEA:Ensembl.
DR   GO; GO:0072687; C:meiotic spindle; IEA:Ensembl.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0030496; C:midbody; TAS:UniProtKB.
DR   GO; GO:0072686; C:mitotic spindle; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0005819; C:spindle; TAS:UniProtKB.
DR   GO; GO:0051233; C:spindle midzone; IBA:GO_Central.
DR   GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035174; F:histone serine kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0051642; P:centrosome localization; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl.
DR   GO; GO:0007067; P:mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:1990138; P:neuron projection extension; IEA:Ensembl.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB.
DR   GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl.
DR   GO; GO:0043146; P:spindle stabilization; IMP:UniProtKB.
DR   InterPro; IPR030616; Aur.
DR   InterPro; IPR030611; AURKA.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24350; PTHR24350; 1.
DR   PANTHER; PTHR24350:SF5; PTHR24350:SF5; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division;
KW   Cilium biogenesis/degradation; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Kinase; Microtubule; Mitosis; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    403       Aurora kinase A.
FT                                /FTId=PRO_0000086692.
FT   DOMAIN      133    383       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     210    213       ATP.
FT   REGION      280    293       Activation segment.
FT   ACT_SITE    256    256       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027,
FT                                ECO:0000269|PubMed:14580337}.
FT   BINDING     143    143       ATP; via amide nitrogen.
FT   BINDING     162    162       ATP.
FT   BINDING     274    274       ATP.
FT   MOD_RES      41     41       Phosphoserine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   MOD_RES      51     51       Phosphoserine.
FT                                {ECO:0000269|PubMed:17229885}.
FT   MOD_RES     287    287       Phosphothreonine.
FT                                {ECO:0000269|PubMed:14580337,
FT                                ECO:0000269|PubMed:19668197}.
FT   MOD_RES     288    288       Phosphothreonine.
FT                                {ECO:0000269|PubMed:11039908,
FT                                ECO:0000269|PubMed:13678582,
FT                                ECO:0000269|PubMed:14580337,
FT                                ECO:0000269|PubMed:14990569,
FT                                ECO:0000269|PubMed:16246726,
FT                                ECO:0000269|PubMed:18662907,
FT                                ECO:0000269|PubMed:19668197}.
FT   MOD_RES     342    342       Phosphoserine; by PKA and PAK.
FT                                {ECO:0000269|PubMed:16246726}.
FT   VARIANT      11     11       G -> R (in dbSNP:rs6069717).
FT                                /FTId=VAR_030840.
FT   VARIANT      31     31       F -> I (in dbSNP:rs2273535).
FT                                {ECO:0000269|PubMed:15867347,
FT                                ECO:0000269|PubMed:16011022,
FT                                ECO:0000269|PubMed:16762494,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9771714}.
FT                                /FTId=VAR_030841.
FT   VARIANT      50     50       P -> L (in dbSNP:rs34572020).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041127.
FT   VARIANT      57     57       V -> I (in dbSNP:rs1047972).
FT                                {ECO:0000269|PubMed:15867347,
FT                                ECO:0000269|PubMed:16011022,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9514916}.
FT                                /FTId=VAR_030842.
FT   VARIANT     104    104       S -> L (in dbSNP:rs2230743).
FT                                /FTId=VAR_061745.
FT   VARIANT     155    155       S -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation; reduces
FT                                interaction with TPX2).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:19801554}.
FT                                /FTId=VAR_041128.
FT   VARIANT     174    174       V -> M (in a metastatic melanoma sample;
FT                                somatic mutation; constitutively enhanced
FT                                kinase activity).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:19801554}.
FT                                /FTId=VAR_041129.
FT   VARIANT     373    373       M -> V (in dbSNP:rs33923703).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041130.
FT   MUTAGEN     162    162       K->R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:14702041,
FT                                ECO:0000269|PubMed:14990569}.
FT   MUTAGEN     165    165       F->A: Decreases the interaction with
FT                                phosphatase type 1 isoforms.
FT                                {ECO:0000269|PubMed:11551964}.
FT   MUTAGEN     198    198       G->N: Reduces interaction with TPX2.
FT                                Reduces kinase activity tenfold. Promotes
FT                                interaction with the AURKB binding
FT                                partners INCENP and BIRC5 that are
FT                                normally not bound by AURKA.
FT                                {ECO:0000269|PubMed:19357306}.
FT   MUTAGEN     205    205       R->A: Reduces ubiquitination and
FT                                proteasomal degradation.
FT                                {ECO:0000269|PubMed:10851084}.
FT   MUTAGEN     274    274       D->N: Abolishes autophosphorylation.
FT                                {ECO:0000269|PubMed:14580337}.
FT   MUTAGEN     287    287       T->A: No direct effect on catalytic
FT                                activity. {ECO:0000269|PubMed:19668197}.
FT   MUTAGEN     287    287       T->E: Enhances interaction with TPX2.
FT                                {ECO:0000269|PubMed:19668197}.
FT   MUTAGEN     288    288       T->D: Mimics phosphorylation state and
FT                                increases kinase activity.
FT                                {ECO:0000269|PubMed:11039908}.
FT   MUTAGEN     346    346       F->A: Decreases the interaction with
FT                                phosphatase type 1 isoforms.
FT                                {ECO:0000269|PubMed:11551964}.
FT   HELIX       130    132       {ECO:0000244|PDB:4J8M}.
FT   STRAND      133    142       {ECO:0000244|PDB:4J8M}.
FT   STRAND      145    152       {ECO:0000244|PDB:4J8M}.
FT   TURN        153    155       {ECO:0000244|PDB:4J8M}.
FT   STRAND      158    165       {ECO:0000244|PDB:4J8M}.
FT   HELIX       166    172       {ECO:0000244|PDB:4J8M}.
FT   HELIX       175    187       {ECO:0000244|PDB:4J8M}.
FT   STRAND      191    193       {ECO:0000244|PDB:3UO6}.
FT   STRAND      196    201       {ECO:0000244|PDB:4J8M}.
FT   STRAND      203    210       {ECO:0000244|PDB:4J8M}.
FT   STRAND      214    217       {ECO:0000244|PDB:2J50}.
FT   HELIX       218    225       {ECO:0000244|PDB:4J8M}.
FT   HELIX       230    249       {ECO:0000244|PDB:4J8M}.
FT   HELIX       259    261       {ECO:0000244|PDB:4J8M}.
FT   STRAND      262    264       {ECO:0000244|PDB:4J8M}.
FT   STRAND      266    268       {ECO:0000244|PDB:3UOL}.
FT   STRAND      270    272       {ECO:0000244|PDB:4J8M}.
FT   STRAND      277    279       {ECO:0000244|PDB:4J8M}.
FT   TURN        283    285       {ECO:0000244|PDB:3H10}.
FT   STRAND      287    289       {ECO:0000244|PDB:4J8M}.
FT   HELIX       290    292       {ECO:0000244|PDB:1MUO}.
FT   HELIX       293    295       {ECO:0000244|PDB:4J8M}.
FT   HELIX       298    301       {ECO:0000244|PDB:4J8M}.
FT   TURN        302    304       {ECO:0000244|PDB:2BMC}.
FT   HELIX       307    309       {ECO:0000244|PDB:2BMC}.
FT   HELIX       310    324       {ECO:0000244|PDB:4J8M}.
FT   HELIX       334    342       {ECO:0000244|PDB:4J8M}.
FT   STRAND      350    352       {ECO:0000244|PDB:1OL6}.
FT   HELIX       354    363       {ECO:0000244|PDB:4J8M}.
FT   HELIX       368    370       {ECO:0000244|PDB:4J8M}.
FT   HELIX       374    378       {ECO:0000244|PDB:4J8M}.
FT   HELIX       381    386       {ECO:0000244|PDB:4J8M}.
SQ   SEQUENCE   403 AA;  45809 MW;  125F3594834CD157 CRC64;
     MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRVPLQ
     AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN
     EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR
     EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL
     ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM
     IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI
     SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS
//
